New Monthly Migraine Injection Eliminates Attacks in 40% of Patients
Quick Facts
How Does the New Migraine Treatment Work?
Calcitonin gene-related peptide (CGRP) plays a central role in migraine pathophysiology. Existing approved therapies — erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) — each target either the CGRP ligand or its receptor, but not both simultaneously. Researchers have been developing bispecific antibodies with two binding domains designed to address both targets at once.
Early Phase 3 trial data in adults with chronic migraine (defined as 15 or more headache days per month) suggest the dual-targeting approach may achieve meaningfully greater reductions in monthly migraine days compared to placebo. Researchers report that a substantial proportion of patients achieved complete migraine freedom during the trial's treatment period — a rate described as nearly double that seen with existing single-target CGRP antibodies.
The rationale for dual blockade is supported by preclinical research suggesting that simultaneously targeting CGRP and its receptor may provide more complete inhibition of trigeminal nerve activation than blocking either target alone.
How Does This Compare to Existing Migraine Treatments?
Current CGRP-targeting therapies have been shown in clinical trials to achieve a 50% or greater reduction in monthly migraine days in approximately 50-60% of chronic migraine patients, with complete freedom rates generally in the range of 15-25%. A large meta-analysis published in JAMA confirmed the efficacy of CGRP monoclonal antibodies across multiple trials, with consistent benefit over placebo.
Early data suggest the bispecific approach may also offer benefit in patients who have had inadequate response to previous CGRP therapies, a population with significant unmet need.
The side effect profile reported in early trial data appears comparable to existing therapies, with injection site reactions and constipation among the most commonly reported adverse events. Regulatory review is anticipated, with a potential decision expected in the coming years pending completion of the full trial program.
Frequently Asked Questions
The trial enrolled adults with chronic migraine (15 or more headache days per month). If approved, it would likely be indicated for patients who have had an inadequate response to prior preventive treatments, consistent with how existing CGRP antibodies are typically prescribed.
Pricing has not been announced. For comparison, existing CGRP antibodies such as erenumab and fremanezumab cost approximately $600-700 per month in the United States before insurance coverage. Patient assistance programs are commonly offered by manufacturers of CGRP therapies.
References
- Ashina M, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485-1495.
- Silberstein SD, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377(22):2113-2122.
- American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1-18.
- Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019;39(3):445-458.